Biotech Values

[25 Kilos of Gold]

http://cellceutix.com/cellceutix-announces-positive-top-line-data-from-phase-2b-absssi-trial-single-dose-brilacidin-comparable-to-7-days-of-daptomycin/#sthash.f7Uzr6ER.dpbs

which comes first events
1) BOD or
2) Up-listing, or
3) Partnership/licensing of B, or
4) The announcement of Cohort 10 for K, or
5) The announcement of the start of the combo trial for K, or
6) The announcement of IND for Phase 2/3 for P, or
7) The announcement of 1st patient dosing and/or additional sites for B-OM Phase 2/3, or
8) Something else like B for eyes and/or ears, Phase 2/3 with B for diabetic foot ulcers, further development of the oral version of B, advancement of the anti-fungal drug candidate(s), further development of our COPD drug, further development of our autism drug candidate, or...
9. MTA with large entity
10. Government Grant
11. Another K P2 planned
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis